Johnson & Johnson (JNJ) Tops Q4 EPS by 4c, Offers FY21 Guidance
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.86, $0.04 better than the analyst estimate of $1.82. Revenue for the quarter came in at $22.5 billion versus the consensus estimate of $21.67 billion.
GUIDANCE:
Johnson & Johnson sees FY2021 EPS of $9.40-$9.60, versus the consensus of $8.99. Johnson & Johnson sees FY2021 revenue of $90.5-91.7 billion, versus the consensus of $89 billion.
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
| ($ in Billions, except EPS) | January 2021 |
Adjusted Operational Sales1,2 Change vs. Prior Year | 8.0% - 9.5% |
Operational Sales2 Change vs. Prior Year | $88.8B - $90.0B 7.5% – 9.0% |
Estimated Reported Sales3 Change vs. Prior Year | $90.5B - $91.7B 9.5% – 11.0% |
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year | $9.25 - $9.45 15.2% - 17.7% |
Adjusted EPS (Diluted)3,4 Change vs. Prior Year | $9.40 - $9.60 17.1% - 19.6% |
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.